Biostem (BSEM) traded down -1.91 % during a 24 hours period ending at 05:43 PM Central Europe on Tuesday 27th. One Biostem stock can currently be bought for about USD 1.5 on popular exchanges. Current supply of Biostem stocks is 20.7 mn. Biostem has a current market capitalization of USD 29.2 mn and approximately USD 261 k worth of Biostem was traded on exchanges in the last 24 hours. Since last month end, Biostem has traded -61.98 % down. Simple moving average of last 200 days is at USD 4.27. The highest price of past 52 weeks was recorded at USD 8.4 on 01/28/2026. 52 weeks low was at USD 1.4 on 10/26/2026.
Here is how related stocks have performed in the past 24 hours:
Rocket Doctor Ai (AIRDF) traded up 2.16 % and now trades at USD 0.33. Rocket Doctor Ai has a market capitalisation of USD 33.5 mn. Rocket Doctor AI Inc. announced that on 23 October 2026 it will grant a series of restricted stock units and stock options to a range of insiders and external parties. The new RSU grant includes 239,000 shares, covering key officers, consultants, and employees, with vesting through 2031. Existing RSU holdings total approximately 4.5 % of the company’s outstanding shares, and the plan reserves additional shares for future issuances. In parallel, a new option pool of 3,143 shares at an exercise price of $0.70 per share is being offered, while outstanding options already represent about 7 % of the shares outstanding. All grants were approved by shareholders in a meeting held in late October 2025 and were announced publicly on 23 October 2026. The company remains in compliance with exchange and securities regulations.
Nanoviricides (NNVC) traded down -2.86 % and now trades at USD 1.46. Current market capitalisation for Nanoviricides is USD 35 mn.
Cervomed (CRVO) traded down -3.03 % and now trades at USD 2.24. Current market capitalisation for Cervomed is USD 34.3 mn.
Lite Strategy (LITS) traded down -3.45 % and now trades at USD 1.16. Current market capitalisation for Lite Strategy is USD 34.4 mn. Lite Strategy, Inc. reported a series of ownership and option transactions in recent SEC filings. Directors and officers, including a CEO/CFO/Secretary, have exercised or been granted stock options at a purchase price of $1.19, with vesting schedules extending to 2036. The company’s board members received options as part of their compensation, with some grants covering 100,000 shares and others covering 600,000 shares. Additionally, the company recorded acquisitions of common stock by a director, increasing his holdings from 1,000 to 2,000 shares over two consecutive days. No significant changes in the company’s control structure were disclosed. The filings reflect routine corporate governance and compensation practices typical for a publicly listed fintech company.
About Biostem
BioStem Technologies, Inc. is a regenerative medicine company that specializes in the stem cell industry for treating a variety of rare and common degenerative diseases. The company has its main operations in Pompano Beach, a health care sector located in the United States. They are also publicly traded on the Other-OTC stock exchange. You can learn more about their work and offerings by visiting their website at www.biostemtech.com .